Skip to search formSkip to main contentSkip to account menu

naroparcil

Known as: (4-(4-cyanobenzoyl)phenyl)-1,5-dithio-beta-D-xylopyranoside 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Thioglycosides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Further Studies on the Mechanism for the Antithrombotic Effects of Naroparcil, an Orally Active Thioxyloside Compound
Summary The antithrombotic β-D-xyloside, naroparcil, has previously been shown to induce a dose-related increase of circulating… 
Highly Cited
1995
Highly Cited
1995
The effect of the beta-D-xyloside naroparcil on circulating plasma glycosaminoglycans. An explanation for its known antithrombotic activity in the rabbit.
Beta-D-Xylosides are known to initiate or prime free glycosaminoglycan (GAG) chain synthesis in cell and tissue culture. As such… 
1995
1995
Reduction of intimal hyperplasia by naroparcil, a 4-methylumbelliferyl beta-D-xyloside analogue, after arterial injury in the hypercholesterolemic rabbit.
4-Methylumbelliferyl beta-D-xylosides (beta-D-xylosides) inhibit proteoglycan synthesis, and this is associated with reduced… 
1995
1995
901-18 Naroparcil, a β-D Xyloside Analog, Limits Intimal Hyperplasia After Arterial Injury
1994
1994
The Venous Antithrombotic Profile of Naroparcil in the Rabbit
Summary The venous antithrombotic profile of naroparcil or (4-[4-cyanoben-zoyl]-phenyl)-1.5-dithio-β-D-xylopyranoside was… 
1992
1992
Oral venous antithrombotic activity of naroparcil (LF 9.0055) in experimental thrombosis
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)